Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 110

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 110
---
 International, Inc., 251 Ballardvale Street, Wilmington, Massachusetts 01887, or by email at CRLLeadDirector@crl.com . In addition to the NHP Report, Charles River also published its extensive and comprehensive biennial Corporate Citizenship Report in March 2024, which includes information on our Global Animal Welfare and Training, Responsible Animal Use and New Alternative Methods (NAMs) work, including investments in NAMs through our Alternative Methods Advancement Project (AMAP) initiative that is dedicated to 82 investing in and developing alternatives to reduce animal testing. Our Corporate Citizenship Report may be accessed at the following link: www.criver.com/annual2025. A summary of our work on NAMs and our AMAP initiative was also provided in the NHP Report. NHPs are Fundamental to Preventing Emerging Infectious Diseases Research animals are a critical resource that furthers our knowledge of living systems and contributes to the discovery of life-saving drugs and other therapies for the treatment and cure of diseases. Before a drug can be evaluated in the clinic on humans, in the absence of a validated alternative, global regulatory agencies generally require testing in two animal species, including one non-rodent species, to ensure patient safety. Because of their close genetic, physiological, and behavioral similarity to humans, NHPs are often the only scientifically relevant animal models for critical translational research and the required safety testing of biologic drugs. As a result, the use of NHPs is fundamental to foundational scientific research and understanding on how to prevent and treat emerging infectious diseases, including the successful development of every COVID-19 vaccine and the work of major academic medical centers. NHPs are also necessary for the development of new innovative treatments for cancer, diabetes, and many other diseases currently without effective treatment options. Charles River is Committed to Ensuring Compliance with Applicable Laws Related to Animal Transportation and Welfare Charles River is committed to ensuring that our operations are compliant with applicable national and international laws and regulations related to animal transportation and welfare, including all required reporting elements. Charles River maintains risk-based supplier due diligence, governance, auditing, and monitoring practices to help ensure the quality of our supply relationships. This includes performing enhanced auditing procedures on NHP suppliers and sharing of best practices and practice improvement opportunities. We acknowledge events during the past two years have raised questions regarding certain aspects of the industry’s NHP supply chains, which are affecting the biomedical research industry, including investigations into shipments of NHPs by our Company from Cambodia. 1 We are committed to